🔗 Share this article

Given that the US proceeds with sweeping changes to its vaccine guidelines, one figure appears unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by questioning COVID-19 vaccines throughout the global health crisis and has concentrated on potential deaths following COVID-19 immunization in her brief tenure at the FDA.

Proposed Shifts to Pediatric Vaccine Program

Agency leaders were set to reveal major changes to the childhood immunization program recently, aligning the US with Denmark’s national calendar, sources say – a substantial departure that would place the US at odds with a large portion of the global community with no evidence for public health gain. The planned update has been delayed until the coming year.

Instead of the top vaccines chief, Høeg is listed to present at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and biologics centers as Høeg and Prasad consolidate power at the agency – and it signals a increased emphasis upon dismantling already-approved vaccines at the FDA.

The new acting director has frequently advocated for discontinuing specific pediatric immunization guidelines in the US in order to be more similar to Denmark's approach, a country with nationalized medicine and a population about the population of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – usually the purview of Prasad, head of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Expertise

The appointee has little discernible experience in drug development, approval processes or leadership, which has been customary for previous directors of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in managing a sizeable institution. She lacks background in drug approvals.”

Past commissioners of the center would “understand regulatory frameworks and the research of drug development”, said Janet Woodcock. “Frankly, she has not acquired the sort of resume that previous people who led the center have had.”

CDER has an vast portfolio at the agency, the former commissioner stated.

“Everybody just zeroes in on the innovative therapies, but the generic drug division authorizes thousands of generic drugs. There is also a biosimilars program, non-prescription drug unit and so forth, and all of those must be looked after,” she noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

There is also, a significant management component to the role, which oversees over 5,000 personnel. “It is a massive management job, if you do it right,” Woodcock added.

Official Statement and Disputed Policies

In response to concerns about Høeg’s qualifications and whether this selection signifies greater collaboration among FDA leaders on immunizations, a press secretary said that the “questions stem from inaccurate presumptions”.

“This background matches the duties of her job,” the official explained, citing the period Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a disputed expedited therapy clearance system that allegedly concerned her preceding directors. “By what process are these drugs being picked for this fast-track system? Who makes the calls?” Dr. Howard said. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed oversight of pharmaceuticals, aside from vaccines.”

Established Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if concerning, track record, some experts observe. She released a research paper using non-validated crowd-sourced reports to assess the rate of myocarditis after Covid vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Included in her “wish list” for the incoming government included revising guidelines for novel immunizations and halting “unnecessary” immunizations, she remarked after the election on a audio program. At the agency, Høeg has reportedly floated the idea of excluding young men from getting Covid vaccines.

“She is an thorough true believer who begins with her preconceived notions and reverse-engineers to fit the science in a highly deceptive, untruthful way,” Howard said.

Taking Control and a “Push for Payback”

Høeg joined other skeptics, {like|